OXFORD, England, May 18 /PRNewswire/ -- PharmaVentures Ltd, announced today that it has been engaged by InDex Pharmaceuticals AB to advise and assist in out-licensing its first in class therapeutic, Kappaproct (DIMS 0150), for the treatment of steroid resistant / dependent Inflammatory Bowel Disease (IBD). The engagement will utilise PharmaVentures’ transactions experience in the healthcare and investment business sectors.
Kappaproct, approved for Orphan Drug Designation in Europe, has recently successfully concluded its third clinical phase II trial for the treatment of Inflammatory Bowel Disease patients. Due to the highly positive interim results at both one and four weeks after dosing, this trial, which included 34 patients and was conducted as a multi-center study in Sweden and Russia, was concluded early. Kappaproct showed the same excellent safety profile as seen in previous trials.
Kappaproct is currently approved for clinical developmental use as a rectal, single-dose administration. Qualification of the compound for other routes of administration and multiple dosing is underway through an extended toxicology program.
Dr Fintan Walton, CEO, PharmaVentures commented, “PharmaVentures is very pleased to be involved in bringing this groundbreaking technology to the market. InDex are leaders in the field of immunomodulation via Toll Like Receptors.”
InDex will be presenting Phase II data at BIO on Wednesday 20th May. See also InDex’s Press Release released today: http://www.indexpharmab.com/images/pdf/kappaproctmay2009.pdf
Visit PharmaVentures during BIO at booths 4209 & 4211 for further information on this and other licensing opportunities.
Notes to Editors:
A leading results driven organisation, PharmaVentures (www.pharmaventures.com) assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company’s core business is the provision of tailored consulting and transaction advisory services to the Life Science industry, with additional deal making support provided through the PharmaDeals range of intelligence products which include analysis tools and reports.
For further information please contact:
InDex Pharmaceuticals AB (“InDex”) is a clinical stage biopharmaceutical company building a leading immunotherapy franchise based on its DIMS platform (DNA-based immunomodulatory sequence). DIMS drugs are developed to treat diseases within a variety of therapeutic areas, including inflammation and cancer. InDex has several proprietary DIMS compounds in various stages of development, including Kappaproct, for the treatment of steroid resistant/dependent ulcerative colitis.
www.indexpharmab.com
CONTACT: Dr Adrian Dawkes, Managing Consultant, +44(0)1865-784-193,
adrian.dawkes@pharmaventures.com, or Fiona Bishop, +44(0)1865-784-187,
fiona.bishop@pharmaventures.com, both of PharmaVentures; or Svante
Rasmuson, CEO, +46(0)8-50-88-47-31, Mobile, +46(0)708-63-93-31,
svante.rasmuson@indexpharmab.com, or Oliver von Stein, CSO,
+46(0)8-50-88-47-32, Mobile, +46(0)708-93-33-75,
oliver.stein@indexpharmab.com, both of InDex Pharmaceuticals
Web site: http://www.pharmaventures.com/
